CTT Pharma CEO Issues Letter to Shareholders

(TheNewswire)

Dear Shareholders,

I want to begin by thanking you for your support and investment inCTT. I believe we are beginning a period of great opportunity andgrowth. Our patented micelle thin-film technology positions CTT to bea unique and powerful force in the drug delivery industry, offeringbetter, faster, and more convenient oral drug delivery options. Myimmediate focus as CEO will be to bring micelle encapsulated vitaminsand other bioactive supplement strips, as well as nicotine oral stripsinto manufacturing in 2026. We are in the final stages of preparing anS-1 that will enable the company to access funding from the equityline and will make us a SEC reporting company. A news release will besent out to shareholders as we get closer to filing the S-1. Being SECreporting is an important step for the company as it will bringadditional transparency and potentially a larger group of shareholdersand investors to CTT Pharma. We hope to be SECReporting before the end of 2025 but understand it could happentowards the beginning of Q1 2026. The capital from this ELOCwill be used towards manufacturing of our patented technology. I wantshareholders to know that I have been be very mindful of our sharecount and dilution and will continue to do so in the future.

CTT is currently in the process of strengthening our team withregulatory experts who can assist us in moving our patented technologythrough the required approval process for sales in North America.Additionally, I am also planning to bring on an additional person toour team who has extensive experience in bringing commercial productsto market.

We are in the process of locating a facility for manufacturing. Ianticipate identifying a building in the first quarter and from therewe will acquire the equipment needed for production.

Additionally, our partnership with Johns Hopkins University, as partof the NIH grant utilizing our technology as a smoking cessationalternative, is still awaiting a funding decision for clinical trials.I will update shareholders immediately once we receive any newinformation. It is important to note that our manufacturing andcommercialization plans are not dependent on the timing of this NIHdecision.

Recently, one of our scientists, Dr. Katharine Cole, together with Dr.Pankaj Modi, the founder of CTT, submitted a scholarly reviewmanuscript to a scientific journal for peer review and potentialpublication. This paper provides a comprehensive review of the currentresearch in micelle/oral dissolvable strip technology. We justreceived feedback from the journal’s peer-review committee, and themanuscript has been accepted for publication on December 15, 2025.This publication will assist us in increasing visibility andunderstanding of the scientific principles that underlie our micelleoral dissolvable strip platform.  We believe this will be a positivestep in educating and engaging shareholders, potential companies thathave an interest in partnering with us, as well as the widerscientific and public communities.  The publication will be sent toshareholders after the publication date next month through a newsrelease. Additionally, I’m looking to schedule a conference call inthe first quarter to discuss CTT’s progress and our upcominginitiatives.

Finally, I have been working to strengthen our patent portfolio andwill share additional information on these patents as more informationdevelops.

Thank you again for your support and trust in CTT’s vision. Withcapital now in place, we are expanding our team, moving towardsmanufacturing, and defining the regulatory paths to commercialization.I look forward to providing additional information soon.

Sincerely,

Ryan Khouri

12/2/25

813-606-0060

(OTCQB-CTTH)

Copyright (c) 2025 TheNewswire - All rights reserved.